Sentence examples for multiple sclerosis study from inspiring English sources

While analysts had generally not expected success in the multiple sclerosis study, expectations were somewhat higher for the lupus trial, despite failures by other companies.

In contrast, studies focusing on specific conditions, such as the overweight Insulin Resistance Atherosclerosis family study, in which only the BsmI SNP [ 22] was analyzed, or the Metabolites in Multiple Sclerosis study, covering ApaI and TaqI SNPs [ 23], did not find an association between VDR polymorphism and 25(OH D levels.

Studies involving HLA-DRB1 have found a link between innate and T-cell-mediated immunity [ 78, 79], and results obtained from a multiple sclerosis study show that the presence of a VDRE (vitamin D response elements) in the proximal promoter region of the HLA-DRB1 gene increased gene expression and imparts 1,25- OH 2-D3 (Vitamin D) sensitivity to the DRB1* 15:01 allele [ 79].

Fifteen of the 59 chronic lesions of multiple sclerosis studied contained areas with increased density of MAP2-positive neurons relative to adjacent non-lesion areas (Fig. 3A C).

Dr Miller has received honoraria through payments to his employer, UCL Institute of Neurology, for advisory committee and/or consultancy advice in multiple sclerosis studies from Biogen Idec, GlaxoSmithKline, Novartis, Merck, Chugai, Mitsubishi Pharma Europe, and Bayer Schering Pharma.

In humans, taking advantage of the inflammatory nature of multiple sclerosis, studies again within our laboratories have shown for the first time a disease-related increase in Purkinje cell fusion and heterokaryon formation.

Because of the focus on Multiple Sclerosis, studies were excluded if they used a mixed sample of various conditions (e.g. studies reported a mixed sample of people with neurological conditions) or if they used a sample of mixed respondents (i.e. people with Multiple Sclerosis and their carers) where results of patients with Multiple Sclerosis could not be clearly separated.

This finding fits well with previous multiple sclerosis studies indicating early pathological changes in the thalamus such as atrophy, altered mean diffusivity, reduced N-acetyl-aspartate concentration and iron accumulation, whereas T2 lesions are more pronounced in the later stages of the multiple sclerosis disease (Minagar et al., 2013).

The first study to explore the effects of early treatment with s.c. IFN-β-1a was the Early Treatment in Multiple Sclerosis (ETOMS) study [7].

Our laboratory uses the Theiler's murine encephalomyelitis virus (TMEV) model of multiple sclerosis to study the mechanisms involved in immune-mediated demyelination.

The Prevention of Relapses and Disability by IFN-β-1a Subcutaneously in Multiple Sclerosis (PRISMS) study established the efficacy of s.c. IFN-β-1a (44 or 22 µg) three times a week (t.i.w).